Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Vaillant

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
Viruses|June 24, 2022
Targeting Subviral Particles: A Critical Step in Achieving HBV Functional Cure but Where Are We with Current Agents in Clinical Development?Andrew Vaillant
Hepatology (Baltimore, Md.)|August 13, 2021
Letter to the Editor: Is the HBsAg response to RO7062931 an antisense effect?Andrew Vaillant
Molecular Therapy. Nucleic Acids|April 11, 2022
Editorial: <i>In vitro</i> mechanistic evaluation of nucleic acid polymers: A cautionary taleAndrew Vaillant
Current Opinion in Virology|February 19, 2018
Letter to the Editor regarding article "Emerging concepts for the treatment of hepatitis delta" [Menashe Elazar and Jeffrey S Glenn, Curr Opin Virol 24 (2017) 55-59]Andrew Vaillant
Hepatology (Baltimore, Md.)|November 13, 2020
Letter to the Editor: Examining HBV-RNA Kinetics During NA Treatment-Are NAs Multifunctional Antiviral Agents?Harel Dahari, Andrew Vaillant, Scott J Cotler
Current Opinion in Virology|May 3, 2017
Letter to the EditorMamun Al-Mahtab, Michel Bazinet, Andrew Vaillant
Antimicrobial Agents and Chemotherapy|August 14, 2013
Nucleic acid polymers inhibit duck hepatitis B virus infection in vitroFaseeha Noordeen, Andrew Vaillant, Allison R Jilbert
Antimicrobial Agents and Chemotherapy|August 14, 2013
Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivoFaseeha Noordeen, Andrew Vaillant, Allison R Jilbert
Plos One|June 4, 2016
Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B InfectionMamun Al-Mahtab, Michel Bazinet, Andrew Vaillant
Plos One|November 1, 2023
Pangenomic antiviral effect of REP 2139 in CRISPR/Cas9 engineered cell lines expressing hepatitis B virus surface antigenLéna Angelo, Andrew Vaillant, Matthieu Blanchet, et al.
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Viruses|June 24, 2022
Targeting Subviral Particles: A Critical Step in Achieving HBV Functional Cure but Where Are We with Current Agents in Clinical Development?Andrew Vaillant
Hepatology (Baltimore, Md.)|August 13, 2021
Letter to the Editor: Is the HBsAg response to RO7062931 an antisense effect?Andrew Vaillant
Molecular Therapy. Nucleic Acids|April 11, 2022
Editorial: <i>In vitro</i> mechanistic evaluation of nucleic acid polymers: A cautionary taleAndrew Vaillant
Current Opinion in Virology|February 19, 2018
Letter to the Editor regarding article "Emerging concepts for the treatment of hepatitis delta" [Menashe Elazar and Jeffrey S Glenn, Curr Opin Virol 24 (2017) 55-59]Andrew Vaillant
Hepatology (Baltimore, Md.)|November 13, 2020
Letter to the Editor: Examining HBV-RNA Kinetics During NA Treatment-Are NAs Multifunctional Antiviral Agents?Harel Dahari, Andrew Vaillant, Scott J Cotler
Current Opinion in Virology|May 3, 2017
Letter to the EditorMamun Al-Mahtab, Michel Bazinet, Andrew Vaillant
Antimicrobial Agents and Chemotherapy|August 14, 2013
Nucleic acid polymers inhibit duck hepatitis B virus infection in vitroFaseeha Noordeen, Andrew Vaillant, Allison R Jilbert
Antimicrobial Agents and Chemotherapy|August 14, 2013
Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivoFaseeha Noordeen, Andrew Vaillant, Allison R Jilbert
Plos One|June 4, 2016
Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B InfectionMamun Al-Mahtab, Michel Bazinet, Andrew Vaillant
Plos One|November 1, 2023
Pangenomic antiviral effect of REP 2139 in CRISPR/Cas9 engineered cell lines expressing hepatitis B virus surface antigenLéna Angelo, Andrew Vaillant, Matthieu Blanchet, et al.
Pageof 6